Summary The human proto-oncogene INT2 (homologous to the mouse INT2 gene, implicated in proviral induced mammary carcinoma) has been mapped to chromosome q 13 and found to share band localisation with, among others, the HSTJ proto-oncogene. Both genes are members of the fibroblast growth factor family. In the present study, coamplification (2-15 copies) of 
The putative proto-oncogene INT2 is known as one of several integration sites for mouse mammary tumour virus (MMTV), a retrovirus implicated in mammary tumourigenesis in certain strains of mice (Nusse, 1988a) . INT2 encodes a predicted member of the fibroblast growth factor (FGF) family of potent mitogens or morphogens involved in angiogenesis, tissue induction and cell migration Thomas, 1988; Burgess, 1988) . The human INT2 gene has been cloned, found to be 89% homologous to the mouse INT2, and mapped to chromosome 11q13 Casey et al., 1986) . Interestingly, another proto-oncogene, HSTJ (HSTFI), was localised to the same chromosomal site and also found to be a FGF member (Adelaide et al., 1988 , Yoshida et al., 1987 , 1988a . HSTI was initially detected as a transforming gene in DNA from human stomach cancer (Sakamoto et al., 1986) , found virtually identical to the KS oncogene from Kaposis sarcoma (Delli Bovi et al., 1987) , and recently also identified as an alternative integration site for MMTV in mouse mammary tumours . INT2 and HST1 are closely linked in the mouse genome (Yoshida et al., 1988b) and only 35 kilobasepairs apart in the same transcriptional orientation in the human genome (Wada et al., 1988) . This suggests that they originated through duplication of a common ancestral gene during evolution, and that this region may involve still other, yet unknown, related genes.
Amplification of the 1 1q13 region have been reported from various solid tumours including, besides breast cancer, squamous cell carcinomas (Zhou et al., 1988 , Berenson et al., 1989 , a stomach cancer and the vulvar carcinoma cell line A431 (Yoshida et al., 1988a) , melanomas (Adelaide et al., 1988 , bladder and Oesophageal carcinomas (Tsutsumi et Tsuda et al., 1988; , and a hepatocellular carcinoma (Hatada et al., 1988) . It usually entails the INT2 and HSTJ genes and also the BCLI locus, recognised as a chromosomal breakpoint in B-cell leukaemia (Tsujimoto et al., 1984) , but not other genes located at the same or neighbouring bands (Ali et al., 1989) . Multiple endocrine neoplasia type I (MEN-I), the pathogenesis of which seems to involve a putative FGF-member, have also been linked to a locus proximal to the INT2 gene at I Iql2-q13 (Nakamura et al., 1989; Bale et al., 1989) . Consequently, although no evidence yet exists, the plain fact that both selective amplifications and non-random translocation encompass the same chromosomal region, points to its importance in the development of human cancer.
In breast cancer, amplification of the INT2 and HSTI genes have been found in 9-23% (Zhou et al., 1988 , Lidereau et al., 1988 Varley et al., 1988; Tsuda et al., 1989; Theillet et al., 1989; Adnane et al., 1989; Fantl et al., 1989 (Casey et al., 1986) ) and the normal, approximately, 2:1 distribution of alleles among studied tumours. Both alleles were found affected by amplification but, in tumours heterozygous for the site, in no cases simultaneously. The HST pORFI probe recognised four constant ECORI digested DNA fragments (Figure 2 ). The three shortest fragments (5.8, 2.8 and 0.8 kb) harbour the HSTJ gene, while the largest fragment (8.0 kb) represents binding to the HST2 gene (Yoshida et al., 1988a Steriod receptor analysis Measurements of Oestrogen (ER) and progesterone receptors (PgR) were performed within two weeks after surgery, at one laboratory and with radioligand binding techniques (isoelectric focusing and dextran-coated charcoal (DCC) with Scatchard analysis, respectively) as described previously (Norgren et al., 1982) . The isoelectric focusing assay has previously been shown to be eqivalent to the DCC assay for ER measurement (Ferno et al., 1983) . Cut-off points of 10 fmol mg-' protein were used for classification of tumours as receptor positive or negative.
Gene analysis DNA was extracted from pulverised tissue (Krieg et al., 1983) and checked for purity and high molecular weight integrity. According to fluorometric determination of DNA concentration, equal amounts (5 gig) of RNAase treated DNA were applied on Zetaprobe nylon membranes using a Bio-Dot SF blotting apparatus (BioRad laboratories, Richmond, CA). Ten tig of BamHI or EcoRI digested DNA were separated in 0.8% agarose gels and transferred to nylon membranes (Southern, 1975 Kaplan and Meier (1958) . Tests of differences between curves were made with the log-rank test for censored survival data (Mantel, 1966) . Multivariate analyses were performed with Cox's partially nonparametric regression model (Breslow, 1975; Cox, 1972) . The Biomedical Computer Program P series (Dixon, 1988) was used in all survival analyses. (Table I) . However, 26 (96%) of the 27 amplified tumours were ER positive, compared with 65% of the unamplified cases (P = 0.001). The ER concentration in amplified tumours was most often of high levels (>200 fmol/mg-' protein, Figure  4 ) and, furthermore, the single deviating sample was not totally devoid of ER, but just below the cut-off value used to classify tumours as ER positive. A similar trend, although not significant, was observed with PgR status. Also shown in Figure 4 is the quite different pattern of ER concentrations in HER-2/neu amplified tumours. HER-2/neu amplification was found in 52 (17%) of the 311 cases . Three of these were also amplified for the 1 1q13 region and, noticeably, also those with the lowest ER concentration among INT2/HSTI amplified cases.
As not all patients were given postoperative radiation and the same, or any, adjuvant therapy, a bias might be introduced in the calculation of survival differences. However, there was no distinction whatever between amplified and unamplified tumours in respect of therapy. Adjuvant tamoxifen, adjuvant chemotherapy and postoperative radiation were given to, respectively, 12 (44%), 2 (7.4%) and 12 (44%) of the 27 amplified tumours, and to, respectively, 106 (37%), 18 (6.3%) and 127 (45%) of the 284 unamplified tumours.
INT2/HSTI amplification in relation to survival INT2/HSTI amplification was found to be a significant predictor of a shorter disease-free survival (DFS, P = 0.015) when analysing all MO patients (n = 291, Figure 5a ). There was a trend towards a worse prognosis of tumours with a (Figure 7) . In the ER Time to disease recurrence (Years) Figure 7 Relationship between INT2/HSTI amplification and disease-free survival in ER positive MO breast cancer. Also shown is the disease-free survival for ER negative. MO breast cancer. positive category, amplification was significantly or nearly significantly correlated also to distant DFS (P = 0.026) and breast cancer survival (P = 0.070).
To examine the significance of INT2/HSTI amplification as a predictor of DFS in combination with other prognostic factors, multivariate analyses (Table II) INT2/HSTI amplification was retained in the model as a nearly significant variable (P = 0.060) with a relative risk of 1.7 for amplified tumours. In node-negative patients, PgR status and INT2/HSTI amplification were the only and approximately equally significant independent variables (P = 0.011 and P = 0.0 13, respectively), with a relative risk of 4.0 (95% confidence interval 1.3-12) for amplified tumours. It should be pointed out that the number of tumours and events in some analyses are small and that the results of these must be cautiously interpreted. 
Discussion
The ability of cancer cells to increase their content of certain macromolecules by gene amplification in response to environmental stress or intratumoural competitive growth, is well established (Schimke, 1984) . In cytogenetic studies of tumour cells grown for short terms to avoid in vitro artefacts, amplified DNA is seen mainly as extrachromosomal chromatin bodies in forms of double minutes or their precursors (Wahl, 1989) . These genetic aberrations replicate autonomously, but lack centromers and are supposed to be randomly distributed during cell division and ultimately lost if not providing a selective growth advantage. The frequent finding of protooncogene amplification in human breast cancer point to its role in disease development. At least three different chromosomal regions are commonly affected; entailing the HER-2/ neu and ERBAI genes at 17qll.2-ql2, the MYC gene at 8q24, and the INT2/HSTI genes at 1lql3 (Callahan, 1989) .
The present study suggests that amplification of the 1 1q13 region in breast cancer occurs in a quite different subset of tumours than affected by HER-2/neu amplification, a conclusion also drawn by Adnane et al. (1989) (Law et al., 1987) mapped to the same chromomsomal site as INT2. The location of the PgR gene was, however, later revised to a more distal site on the long arm (1 lq22-q23, Rousseau-Merck et al., 1987 . The PgR gene was in the present study also found in no case to be coamplified with the genes at 1q13.
No evidence exists as yet for a specific physiological role of INT2 or HSTJ in humans. An activity of the genes during mesoderm induction was, however, demonstrated in amphibian embryos (Paterno et al., 1989) . Mouse HSTJ was found expressed during a short interval in midstage embryos (Terada et al., 1989) . The normal activity of INT2 in mice is also confined to the early embryonic development, where a stimulation of cell migration and tissue induction rather than of cell proliferation and angiogensis was suggested (Wilkinson et al., 1989) . Its reactivation in the adult mouse mammary gland by inserted proviral enhancers points to a causative role in the subsequent neoplastic formation. Interestingly, these tumours are initally hormone-dependent in that they arise only after several pregnancy cycles and regress between pregnancies. When tumours eventually progress to become autonomous, this seems to occur irrespective of further INT2 activity (Peters et al., 1984; Nusse, 1988b) . A similar synergism between INT2 or HSTI and sex hormones in the earlier development of certain human breast cancers is conceivable, the former acting as inducers and the latter as promoters.
Arguing against this is the fact that INT2/HSTI amplification is found also in other malignancies in general considered not to be hormone-responsive. Also, it still remains to be confirmed that amplification of the genes actually coincides with a transcriptional activation, a controversial subject in human breast cancer: Liscia et al. (1989) used RNA:RNA in situ hybridisation and Northern blot analysis to show that some INT2/HSTJ amplified tumours contained INT2, but not HSTI, transcripts, implying that INT2 is the probable gene of significance in the amplicon. Several mRNA species of different sizes (2.4-4.6 kb) were observed (Liscia et al., 1989) , none however equivalent to the single 1.7 kb INT2 transcript detected in teratocarcinoma cell lines and predicted from the physical map of the INT2 gene (Fantl et al., 1989) . On the contrary, Theillet et al. (1989) saw both INT2 and HSTI transcripts with RNA:RNA in situ hybridisation, but found connection to gene amplification only in the case of HSTI. Moreover, Fantl et al. (1989) , using a sensitive RNAase protection assay to analyse both INT2 amplified and unamplified tumours, were unable to detect any expression of INT2 or HSTI and suggested that another gene in the vicinity of INT2 may be of importance. Terada et al. (1989) , analysing a variety of cancerous and non-cancerous human cells and tissues for HSTI transcripts, also reported on negative findings except in some cases of testicular germ-cell tumours and a teratoma cell line. It must however be remembered that even a low level of expression of normally silent genes may be sufficient to induce aberrant growth. Neither can it be excluded that the findings of gene amplification in these clinical tumours is a reminiscence of an earlier activity.
Nevertheless, amplification of the l1ql3 region has been shown to be associated with a poor clinical outcome (Lidereau et al., 1988; Zhou et al., 1988; Tsuda et al., 1989) . A prognostic value of gene amplification in prediction of disease-free survival was confirmed in the present study, found to persist in multivariate analysis and to be confined to node-negative patients. A subset of these latter patients, a group in general considered as being of good prognosis, could be separated and shown to have a disease-free survival as bad as node-positive patients. At this median time of 46 months follow-up, the correlations had not yet translated into survival differences. As the number of cases and relapse events in the node-negative group are small, the results must be critically interpreted. However, if shown to be valid in future investigations, amplification of this chromosomal region may become an important prognostic factor and useful in selection of node-negative patients for adjuvant therapy. Also, an increased knowledge of the genes at 1 1q13 will most certainly contribute to a deeper understanding of human breast cancer etiology.
